[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mitochondrial-energetics\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mitochondrial-energetics":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,51],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":35,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":5},"100438049","phase-2-sodium-bicarbonate-and-mitochondrial-energetics-in-persons-with-ckd-100438049",false,"NCT04984226","Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD","Randomized Cross-over Trial of Sodium Bicarbonate on Muscle Mitochondrial Energetics and Physical Endurance in Chronic Kidney Disease and Metabolic Acidosis","Senergy-CKD","Inclusion Criteria:\n\n* Moderate-severe CKD determined by eGFR \\\u003C50ml\u002Fmin per 1.73m2 by CKD EPI equation on at least 2 consecutive occasions.\n* Metabolic acidosis defined as bicarbonate level\\\u003C24 on two consecutive occasions. Bicarbonate level of 24 or less allowed if eGFR\\\u003C=45ml\u002Fmin per 1.73m2\n* Age 21 to 85 years old\n\nExclusion Criteria:\n\n* Type 1 diabetes\n* Poorly controlled diabetes (HgbA1c\\>10%)\n* History of persistent hyperkalemia (K\\>5.4)\n* History of persistent hypokalemia (K\\\u003C3.3)\n* Uncontrolled blood pressure (\\>170\u002F100)\n* Chronic treatment with renal replacement therapy\n* History of aortic dissection or severe valvular heart disease\n* Exercise induced angina\n* Uncontrolled cardiac dysrhythmia\n* Oxygen dependent chronic obstructive pulmonary disease (COPD)\n* Symptomatic claudication\n* End stage liver disease\n* Mobility disability defined as inability to walk without human assistance\n* Dementia or psychosis\n* Patients who cannot consent\n* Active use of intraveneous drugs\n* Non-english speaking\n* History of transplant\n* Implants that prohibit MRI measurements or trauma involving metal fragments\n* Pacemaker\n* Expectation to start dialysis during the course of study.\n* Women who are breastfeeding, pregnant, or are wanting to become pregnant\n* Any condition which in the judgement of the clinical investigator places the participant at risk from participation in the study.\n\nExclusion criteria for optional muscle biopsy\n\n* Drugs- anticoagulants or antiplatelets:\n\n  * Anticoagulants, any 1 (coumadin, rivaroxaban, apixaban, dabigatran, edoxaban)\n  * Antiplatelets, any 2 (aspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, ticragrelor, ticlopidine, vorapaxar)\n* Platelet count \\\u003C100,000\n* International normalized ratio (INR)\\>1.4","ALL","21 Years","85 Years",{"count":21,"type":22},80,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","Skeletal muscle metabolic health is critical for mobility and an underrecognized target of metabolic acidosis in chronic kidney disease. Impaired muscle mitochondrial metabolism underlies poor physical endurance increasing the risk of mobility disability. The proposed project will use precise in vivo tools to study the pathophysiology of poor physical endurance in a clinical trial treating metabolic acidosis among persons living with chronic kidney disease.",[28,29,30,31,32,33,34],"Chronic Kidney Diseases","Metabolic Acidosis","Fatigue","Physical Endurance","Insulin Resistance","Mitochondrial Energetics","Diabetes",[36,37,38],"Metabolic acidosis","Chronic kidney disease","Insulin resistance","RECRUITING","2026-05-04",{"date":42,"type":43},"2026-05-06","ACTUAL",{"date":45,"type":43},"2023-09-08",{"date":47,"type":22},"2026-12-31",{"name":49,"class":50},"University of California, Davis","OTHER",{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":23,"phases":64,"briefSummary":66,"conditions":67,"keywords":70,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":78,"locationsCount":80},"100605396","effect-of-dietary-nitrate-on-immobilization-induced-changes-in-skeletal-muscle-in-young-healthy-men-100605396","NCT07161973","Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men","Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle","Inclusion Criteria:\n\n* Men age 18-44\n* Above the minimum threshold of the IPAQ questionnaire\n* Below the maximum threshold of the IPAQ questionnaire\n\nExclusion Criteria:\n\n* Men and women \\\u003C18 or \\>44 years of age\n* Unable to provide informed consent\n* Known clotting disorder\n* Previous history of deep vein thrombosis\n* Injury to either leg resulting in reduced mobility in the previous year\n* Currently dieting or weight instability for the past 3 months\n* Epileptic\n* Pacemaker or other implantable heart device\n* Currently taking antibiotics\n* Current smoker\n* Stage II hypertension (resting blood pressure \\>140\u002F\\>90)\n* Previously undergone a revascularization procedure involving a vascular graft or stenting of the femoral or popliteal arteries\n* Those taking phosphodiesterase inhibitors (e.g., Viagra), proton pump inhibitors, antacids, xanthine oxidase inhibitors, hormonal contraceptives or on hormone replacement therapy\n* An answer of yes to any of the seven questions on the first page of the Physical Activity Readiness Questionnaire (PAR-Q. These exclusions include the following:\n\n  * If participant's doctor has ever said that he\u002Fshe has a heart condition and that he\u002Fshe should only do physical activity recommended by a doctor\n  * Pain in chest when doing physical activity\n  * In past month, chest pain when not doing physical activity\n  * If participant has ever lost balance because of dizziness or has ever lost consciousness\n  * Muscle, bone, or joint problem that could be made worse by physical activity\n  * Currently on prescribed drugs for blood pressure or heart condition.\n  * If the participant knows of any other reason he\u002Fshe should not do physical activity.",true,"MALE","18 Years","44 Years",{"count":63,"type":22},24,[65],"NA","Diminished use of skeletal muscle, such as occurs with many chronic diseases (e.g., heart failure or cancer cachexia), denervation, bedrest, immobilization (e.g., limb casting or bracing), etc., is a common clinical condition affecting untold millions of individuals each year. Such disuse leads to a rapid decline in muscle fiber area and hence whole muscle size, contributing to a decrease in strength, speed, and power as well as alterations in energy metabolism. Collectively, these changes lead to reduced physical function and contribute to the seriousness of any disease, illness (e.g., pneumonia), surgery (e.g., joint replacement), or injury (e.g., broken bone) accompanied by decreased muscular activity. Currently, there are no effective pharmacological treatments to prevent disuse-associated muscle wasting in humans.\n\nThe above-described effects of disuse appear to be due, at least in part, to a decrease in nitric oxide (NO) bioavailability. Reduced synthesis of NO and\u002For increased NO destruction (due to increased production of oxygen free radicals) likely contributes to the mitochondrial changes, energetic abnormalities, and muscle atrophy resulting from immobilization. The objective of this study is to investigate the potential benefits of dietary nitrate supplementation on immobilization-induced changes in muscle contractile function and mitochondrial respiratory capacity in young healthy men. Our disuse-induced muscle atrophy model will involve wearing a knee brace for a period of 14 d.",[33,68,69],"Dietary Nitrate","Disuse Atrophy (Muscle) of Lower Leg",[68,71],"Immobilization","2026-02-20",{"date":74,"type":43},"2026-02-23",{"date":76,"type":43},"2026-01-30",{"date":47,"type":22},{"name":79,"class":50},"Indiana University",1]